Dexcom (DXCM) Cash from Investing Activities (2010 - 2026)

Dexcom (DXCM) has reported Cash from Investing Activities for 17 consecutive years, with $329.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 618.55% year-over-year to $329.8 million; the TTM figure through Jun 2026 stood at $530.7 million (up 1034.33% YoY), while the FY2025 annual figure was $536.0 million, up 358.31% from the prior year.
• Cash from Investing Activities climbed to $329.8 million in Q2 2026 per DXCM's latest filing, from -$298.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $414.9 million in Q4 2023 and bottomed at -$555.9 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged -$37.2 million across 5 years, with a median of -$104.2 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 690.69% — and 2026, when it sank 397.9%.
• Dexcom's Cash from Investing Activities stood at -$194.1 million in 2022, then soared by 313.76% to $414.9 million in 2023, then plunged by 173.2% to -$303.7 million in 2024, then surged by 200.95% to $306.6 million in 2025, then climbed by 7.57% to $329.8 million in 2026.
• Business Quant data shows DXCM's Cash from Investing Activities at $329.8 million in Q2 2026, -$298.5 million in Q1 2026, and $306.6 million in Q4 2025.